Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2014

View Archived Issues

Safety issues noted in phase I study of cabazitaxel in gastric adenocarcinoma

The Vanderbilt University patents novel mGlu5 receptor modulators

Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial

Simtuzumab well tolerated in phase I and II trials

Nektar Therapeutics reviews product development status for 2014

Preliminary trial results provided for selinexor in colorectal cancer

Hybrigenics achieves first milestone under USP collaboration

Novel antibodies for cancer presented by Regeneron Pharmaceuticals

4SC Discovery discloses new casein kinase inhibitors

French and Danish researchers patent new K(Ca)3.1 channel blockers

Cystadane approved in Japan for homocystinuria

A team in Israel divulges new anti-fibrinolytic compositions for coagulation

Roche and Genentech synthesize new pim kinase inhibitors

Amarin to appeal FDA's rescindment of ANCHOR SPA agreement

Novartis synthesizes new agents for macular degeneration and other disorders

Phase I study begins for hemophilia candidate ALN-AT3SC

Pluristem's phase I/II trial of PLX-PAD cells in muscle injury meets primary endpoints

New radioligands tested for assessment of AD in living subjects

GSK launches phase I trial of GSK-2879552 in relapsed/refractory SCLC

First trials in phase III bitopertin program miss primary endpoints

Novartis opens phase II study of VAY-736 in multiple sclerosis

Eculizumab receives FDA orphan drug designation for delayed graft function in renal transplantation

French authorities grant temporary authorization for use of Raxone in LHON

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...